Dna X (SONM) Receivables - Other (2020 - 2025)

Dna X has reported Receivables - Other for 6 years, with the latest figure at $9.8 million in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other rose 1428.11% year-over-year to $9.8 million; the trailing twelve-month figure through Sep 2025 stood at $9.8 million (up 1428.11% YoY), and the FY2024 full-year result was $181000.0, down 81.17% from the prior year.
• Receivables - Other for Q3 2025 stood at $9.8 million, up from $7.0 million in the prior quarter.
• The five-year high for Receivables - Other was $9.8 million in Q3 2025, with the low at $181000.0 in Q4 2024.
• Historically, Receivables - Other has averaged $2.8 million across 5 years, with a median of $1.9 million in 2021.
• Annual changes were most pronounced in 2024 — Receivables - Other plunged 81.17% — and 2025, when it surged 1428.11%.
• Dna X's Receivables - Other stood at $2.3 million in 2021, then increased by 0.62% to $2.3 million in 2022, then slumped by 57.65% to $961000.0 in 2023, then tumbled by 81.17% to $181000.0 in 2024, then jumped by 5337.02% to $9.8 million in 2025.
• The last three Receivables - Other figures came in at $9.8 million (Q3 2025), $7.0 million (Q2 2025), and $6.5 million (Q1 2025), per Business Quant data.